Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Chief Accounting Officer | December 11, 2018 | December 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date December 11, 2018 · Filed December 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2028-12-11 | Direct | 7,500 |
Reported balance
After 2018-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-11 · Grant · Acquired 7,500 · Balance 7,500 F1: The option will vest on termination of employment. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest on termination of employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2018 Filed Dec 13, 2018 15:11 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001123292-18-001115 · edgar.xml · derivative · entry 1 VandenEnden Koert · CIK 0001732118 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 7,500 shares Expires 2028-12-11 F1 · derivative.exercise_price: The option will vest on termination of employment. F1 · derivative.exercise_date: The option will vest on termination of employment. Read SEC document |
| April 16, 2018 Filed Apr 17, 2018 20:20 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001140361-18-018861 · doc1.xml · derivative · entry 1 VandenEnden Koert · CIK 0001732118 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-16 F1 · derivative.exercise_date: The options will vest on termination of employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.